ÂÜÀòÂÒÂ×

Dr. Jeremiah Degenhardt joined ImmuneID in January 2022 to oversee the company’s data management, bioinformatics and machine learning/AI activities. His career in oncology research and development began over 11 years ago, during which time he has built expertise in next-generation sequence analysis, high-performance computing systems, target discovery, evaluation of mechanisms of resistance, and biomarker discovery. Prior to ImmuneID, he was with Maverick Therapeutics where he was Vice President of Translational Oncology & Bioinformatics and a member of the Joint Steering Committee with Takeda Pharmaceutical Company and played a pivotal role in designing and communicating the company’s target and indication prioritization strategy. Before Maverick, he held roles of increasing responsibility focused on the development and deployment of computational infrastructure supporting genomics, bioinformatics and biomarker discovery programs at Genentech, Onyx Pharmaceuticals and Gilead Sciences. Dr. Degenhardt also provided expert counsel in areas including genomics, bioinformatics and computational infrastructure at Identify Genomics.

He received a BS in zoology from the University of Idaho and a Ph.D. in computational biology from Cornell University, where he focused on theoretical population genetics and genome evolution under the mentorship of Professor Carlos D. Bustamante.